Aquoral gains new distribution through MVAP Medical Supplies

K Pharmaceuticals has added MVAP Medical Supplies as a distribution partner for Aquoral Protective Oral Spray, expanding prescription access for dry-mouth treatment in sleep medicine and respiratory care. The product is now available through MVAP’s catalog for sleep labs, providers and healthcare facilities nationwide.

Why it matters: - The partnership gives sleep and respiratory care providers another way to order Aquoral, a prescription option for dry mouth that can affect comfort during PAP therapy. - The move could help more patients dealing with xerostomia get treatment through the supply channels their providers already use. - Dry mouth can affect sleep, speaking, eating and swallowing, and can raise the risk of tooth decay and oral infections.

What happened: - K Pharmaceuticals announced a distribution partnership with MVAP Medical Supplies on September 10, 2026. - Aquoral Protective Oral Spray is now available for purchase through the MVAP Medical Supplies catalog. - The product is being positioned for use across the sleep and respiratory care community. - MVAP serves sleep labs, hospitals and healthcare facilities nationwide.

The details: - Aquoral is an FDA-cleared, prescription Class II medical device indicated for the relief of chronic and temporary dry mouth, also known as xerostomia. - Aquoral uses oxygenated glycerol triester, or OGT, technology designed to spread across the oral mucosa and form a protective lipid film. - The formulation is designed to provide sustained lubrication and remain on oral tissues longer than traditional water-based saliva substitutes. - MVAP’s catalog already includes sleep diagnostics, home sleep testing, respiratory care and CPAP/patient-care products. - K Pharmaceuticals said the product is easier to access through channels sleep professionals already know and use. - Brent Mjoen, COO of MVAP Medical Supplies, said the company’s national reach makes the partnership worthwhile. - Peter Allen, national clinical specialist for Aquoral, said the addition to the MVAP catalog broadens access across the sleep-care community. - Aquoral is indicated for relief of both chronic and temporary dry mouth. - The company uses the plain-language term dry mouth in education and communication while recognizing xerostomia as the clinical term.

Between the lines: - Dry mouth is common in patients with obstructive sleep apnea and among people using CPAP therapy. - A prospective study found morning xerostomia in 45% of people with sleep apnea, compared with 20.4% of controls. - Among study participants using CPAP, 57.1% reported dry mouth on waking. - The partnership reflects a push to make dry-mouth treatment more visible inside sleep medicine, where symptoms are often overlooked. - Adding Aquoral to an established sleep-care catalog may make it easier for providers to pair the treatment with other routine orders.

What's next: - Aquoral is now available for purchase through MVAP Medical Supplies. - Sleep labs, respiratory providers and other healthcare organizations that buy through MVAP can begin accessing the product through that channel. - K Pharmaceuticals and MVAP are positioning the partnership as a broader route to patient access in sleep care.

The bottom line: - Aquoral’s new MVAP channel could make a prescription dry-mouth treatment easier for sleep providers to obtain and prescribe to patients who need relief.